Enzalutamide Clinical Trials
Browse 9 Enzalutamide Medical Studies Across 116 Cities
3 Phase 3 Trial · 176 Enzalutamide Clinics
NUV-868for Pancreatic Cancer
Talazoparib Plus Enzalutamidefor Prostate Cancer
PF-07220060for Lung Adenocarcinoma
Tazemetostatfor Prostate Cancer
HC-1119for Prostate Cancer
Enzalutamidefor Prostate Cancer
LY2157299for Prostate Cancer
Enzalutamidefor Prostate Cancer
Enzalutamidefor Breast Cancer
What Are Enzalutamide Clinical Trials?
Enzalutamide clinical trials are research studies that help test the effectiveness of the medication. The medication is used as a treatment for prostate cancer.
Current treatments for prostate cancer include surgery, radiation therapy, and hormone therapy. Enzalutamide is a new type of medication that blocks testosterone's activity. This may help to slow the growth of cancer cells.
Enzalutamide clinical trials are being conducted to see if this medication effectively treats prostate cancer. These trials are also being conducted to compare Enzalutamide's effectiveness with other prostate cancer treatments.
Why Is Enzalutamide Being Studied in Clinical Trials?
Enzalutamide has recently been FDA-approved for prostate cancer treatment that has spread to other parts of the body and is resistant to hormone therapy. Enzalutamide clinical trials are being conducted to test the medication's effectiveness in treating this type of prostate cancer.
Enzalutamide is hypothesized to be more effective than current prostate cancer treatments. It may also have fewer side effects than other prostate cancer treatments.
Common treatments for prostate cancer are surgery, radiation therapy, and hormone therapy. Surgery may not be the best treatment because it can cause urinary incontinence and erectile dysfunction.
Radiation therapy may not be the best treatment because it can cause fatigue and skin problems. Hormone therapy may not be the best treatment because it can cause hot flashes, weight gain, and loss of bone density. Enzalutamide clinical trials are being conducted to see if this medication is an effective treatment with fewer side effects.
How Does Enzalutamide Work?
Enzalutamide works by blocking testosterone's activity. This may help to slow the growth of cancer cells.
Testosterone is a hormone that helps to stimulate the growth of prostate cancer cells. Enzalutamide works by binding to the androgen receptor, and the protein testosterone binds to it. The chemical blocks testosterone from binding to the androgen receptor and may help slow cancer cell growth.
Enzalutamide may also help kill cancer cells and prevent them from growing and spreading. However, it may work better when combined with other prostate cancer treatments.
What Are Some of The Breakthrough Clinical Trials Involving Enzalutamide?
Some breakthrough clinical trials with Enzalutamide include:
2013: A clinical study tested the first round of Phase I tests on males with prostate cancer using Enzalutamide. The results proved that Enzalutamide was well tolerated by the patients and had a good safety profile.
2017: This study found that Enzalutamide, in combination with Endocrine Therapies, was a well-tolerated treatment option for women with advanced breast cancer. This was a breakthrough because it was unclear if Enzalutamide would effectively treat other types of cancer.
2023: Enzalutamide was tested to see if it was more effective than Bicalutamide in patients with nonmetastatic castration-resistant prostate cancer. The findings were that Enzalutamide lowered the risk progression of death better than Bicalutamide.
Who Are The Key Opinion Leaders On Enzalutamide Clinical Trial Research?
Dr. Maha Hussain: She is the Director of the USC Norris Comprehensive Cancer Center and a Professor of Medicine at the Keck School of Medicine of USC.
Dr. Scott Eggener: He is a Professor of Surgery and Urology at the University of Chicago. He has also been involved in Enzalutamide clinical trials and is a leading expert in the field.
Dr. Christopher Sweeney is a Medicine Professor at the Dana-Farber Cancer Institute and Harvard Medical School. He is also the Director of Genitourinary Oncology at the Dana-Farber Cancer Institute.